Lynn Vitale-Cross
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lynn Vitale-Cross has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Alfredo Molinolo
Moores Cancer Center, University of California San Diego, San Diego, CA 92093, USA
19 shared publications Amy Wahba
19 shared publicationsDana J. Steffen
19 shared publications- Daniel Martin
Genomics and Computational Biology Core, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
19 shared publications Joseph Califano
19 shared publicationsMichael Allevato
19 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2408-2416
Osteocyte-derived erythroferrone regulates liver hepcidin during stress erythropoiesis
Our knowledge of which bone marrow (BM) cells affect red cell production is still incomplete. To explore the role of osteocytes in the process, we performed bulk RNA sequencing of osteocytes isolated from control and phlebotomized mice. The second top upregulated gene after phlebotomy was erythroferrone (Erfe). Erfe expression in osteocytes was also upregulated after erythropoietin (EPO) treatment and hypoxia in vitro. To explore whether osteocytes contribute to systemic ERFE levels, we generated 2 mouse models. We first transplanted wild-type BM in Erfe−/− mice, creating a model where ERFE is produced in the BM but not by osteocytes. After phlebotomy, liver hepcidin suppression was significantly lower in mice where the osteocytes could not produce ERFE. To confirm that osteocytes are responsible for this difference, we generated mice lacking EPO receptors in osteocytes by crossing Eporflox/flox and Dmp1-Cre mice. After phlebotomy, these mice demonstrated reduced hepcidin suppression in the liver and higher circulating serum hepcidin levels compared with controls. Our work identified a novel function of osteocytes in suppressing systemic hepcidin levels during stress erythropoiesis.
- 1 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2408-2416
Open AccessOsteocyte-derived erythroferrone regulates liver hepcidin during stress erythropoiesis
Our knowledge of which bone marrow (BM) cells affect red cell production is still incomplete. To explore the role of osteocytes in the process, we performed bulk RNA sequencing of osteocytes isolated from control and phlebotomized mice. The second top upregulated gene after phlebotomy was erythroferrone (Erfe). Erfe expression in osteocytes was also upregulated after erythropoietin (EPO) treatment and hypoxia in vitro. To explore whether osteocytes contribute to systemic ERFE levels, we generated 2 mouse models. We first transplanted wild-type BM in Erfe−/− mice, creating a model where ERFE is produced in the BM but not by osteocytes. After phlebotomy, liver hepcidin suppression was significantly lower in mice where the osteocytes could not produce ERFE. To confirm that osteocytes are responsible for this difference, we generated mice lacking EPO receptors in osteocytes by crossing Eporflox/flox and Dmp1-Cre mice. After phlebotomy, these mice demonstrated reduced hepcidin suppression in the liver and higher circulating serum hepcidin levels compared with controls. Our work identified a novel function of osteocytes in suppressing systemic hepcidin levels during stress erythropoiesis.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Aberrant activation of the PI3K–mTOR signaling pathway occurs in >80% of head and neck squamous cell carcinomas (HNSCC), and overreliance on this signaling circuit may in turn represent a cancer-specific vulnerability that can be exploited therapeutically. mTOR inhibitors (mTORi) promote tumor regression in genetically defined and chemically induced HNSCC animal models, and encouraging results have been recently reported. However, the mTOR-regulated targets contributing to the clinical response have not yet been identified. Here, we focused on EIF4E-BP1 (4E-BP1), a direct target of mTOR that serves as key effector for protein synthesis. A systematic analysis of genomic alterations in the PIK3CA–mTOR pathway in HNSCC revealed that 4E-BP1 is rarely mutated, but at least one 4E-BP1 gene copy is lost in over 35% of the patients with HNSCC, correlating with decreased 4E-BP1 protein expression. 4E-BP1 gene copy number loss correlated with poor disease-free and overall survival. Aligned with a tumor-suppressive role, 4e-bp1/2 knockout mice formed larger and more lesions in models of HNSCC carcinogenesis. mTORi treatment or conditional expression of a mutant 4E-BP1 that cannot be phosphorylated by mTOR was sufficient to disrupt the translation–initiation complex and prevent tumor growth. Furthermore, CRISPR/Cas9–targeted 4E-BP1 HNSCC cells resulted in reduced sensitivity to mTORi in vitro and in vivo. Overall, these findings indicate that in HNSCC, mTOR persistently restrains 4E-BP1 via phosphorylation and that mTORi can restore the tumor-suppressive function of 4E-BP1. Our findings also support 4E-BP1 expression and phosphorylation status as a mechanistic biomarker of mTORi sensitivity in patients with HNSCC.Significance:These findings suggest that EIF4E-BP1 acts as a tumor suppressor in HNSCC and that 4E-BP1 dephosphorylation mediates the therapeutic response to mTORi, providing a mechanistic biomarker for future precision oncology trials.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Aberrant activation of the PI3K–mTOR signaling pathway occurs in >80% of head and neck squamous cell carcinomas (HNSCC), and overreliance on this signaling circuit may in turn represent a cancer-specific vulnerability that can be exploited therapeutically. mTOR inhibitors (mTORi) promote tumor regression in genetically defined and chemically induced HNSCC animal models, and encouraging results have been recently reported. However, the mTOR-regulated targets contributing to the clinical response have not yet been identified. Here, we focused on EIF4E-BP1 (4E-BP1), a direct target of mTOR that serves as key effector for protein synthesis. A systematic analysis of genomic alterations in the PIK3CA–mTOR pathway in HNSCC revealed that 4E-BP1 is rarely mutated, but at least one 4E-BP1 gene copy is lost in over 35% of the patients with HNSCC, correlating with decreased 4E-BP1 protein expression. 4E-BP1 gene copy number loss correlated with poor disease-free and overall survival. Aligned with a tumor-suppressive role, 4e-bp1/2 knockout mice formed larger and more lesions in models of HNSCC carcinogenesis. mTORi treatment or conditional expression of a mutant 4E-BP1 that cannot be phosphorylated by mTOR was sufficient to disrupt the translation–initiation complex and prevent tumor growth. Furthermore, CRISPR/Cas9–targeted 4E-BP1 HNSCC cells resulted in reduced sensitivity to mTORi in vitro and in vivo. Overall, these findings indicate that in HNSCC, mTOR persistently restrains 4E-BP1 via phosphorylation and that mTORi can restore the tumor-suppressive function of 4E-BP1. Our findings also support 4E-BP1 expression and phosphorylation status as a mechanistic biomarker of mTORi sensitivity in patients with HNSCC.Significance:These findings suggest that EIF4E-BP1 acts as a tumor suppressor in HNSCC and that 4E-BP1 dephosphorylation mediates the therapeutic response to mTORi, providing a mechanistic biomarker for future precision oncology trials.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Supplementary Figure S6 shows (A) Western blot analysis, (B) m7GTP pull down, (C) eIF4G co-IP analyzing the regulation of the translation initiation complex formation by mTOR inhibition; and D, densitometry analysis of western blots in Figure S6B.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Supplementary Figure S6 shows (A) Western blot analysis, (B) m7GTP pull down, (C) eIF4G co-IP analyzing the regulation of the translation initiation complex formation by mTOR inhibition; and D, densitometry analysis of western blots in Figure S6B.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Supplementary Figure S4 shows (A) Western blot analysis, (B) m7GTP pull down, (C) eIF4G co-IP analyzing the regulation of the translation initiation complex formation by 4E-BP1; D, densitometry analysis of western blots in Figure S4B; E, tumor growth curve and F, representative histological tissue sections of HN12 cells expressing empty vector (iG) or 4EBP1 M (iG 4E-BP1).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Supplementary Figure S4 shows (A) Western blot analysis, (B) m7GTP pull down, (C) eIF4G co-IP analyzing the regulation of the translation initiation complex formation by 4E-BP1; D, densitometry analysis of western blots in Figure S4B; E, tumor growth curve and F, representative histological tissue sections of HN12 cells expressing empty vector (iG) or 4EBP1 M (iG 4E-BP1).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Supplementary Figure S1 shows A, EIF4E-BP1 alterations in HNSCC; B, EIF4E-BP1 expression and HNSCC survival; C, 4E-BP1 re-expression analysis; and D, Spearman rank correlation coefficient analysis of EIF4E-BP1.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Supplementary Figure S1 shows A, EIF4E-BP1 alterations in HNSCC; B, EIF4E-BP1 expression and HNSCC survival; C, 4E-BP1 re-expression analysis; and D, Spearman rank correlation coefficient analysis of EIF4E-BP1.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Supplementary Figure S5 shows A, western blot analysis of 4E-BP1 regulation by mTOR, not ERK; B, densitometry analysis of figure 3B; and C, densitometry analysis of figure 4B.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Supplementary Figure S5 shows A, western blot analysis of 4E-BP1 regulation by mTOR, not ERK; B, densitometry analysis of figure 3B; and C, densitometry analysis of figure 4B.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Supplementary Figure S2 shows A, the first intron of EIF4E-BP1 as an active target for epigenetic regulation of transcription; and B, 4NQO-induced tumors in eif4e-bp1/2 KO mice.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Supplementary Figure S2 shows A, the first intron of EIF4E-BP1 as an active target for epigenetic regulation of transcription; and B, 4NQO-induced tumors in eif4e-bp1/2 KO mice.